thiotepa has been researched along with Hematologic Malignancies in 26 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and antithymocyte globulin (ATG)." | 7.70 | Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. ( Bacigalupo, A; Barbanti, M; Berisso, G; Bregante, S; Bruno, B; Casarino, L; Di Grazia, C; Dominietto, A; Ficai, G; Ghinatti, C; Gualandi, F; Lamparelli, T; Raiola, AM; Sacchi, N; Sessarego, M; van Lint, MT; Verdiani, S, 2000) |
| "All but four had advanced hematologic malignancies." | 6.71 | Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. ( Amin, K; Chen, YH; Cheung, T; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sosman, J; Stock, W; van Besien, K; Vijayakumar, S; Wickrema, A; Yassine, M, 2003) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and mycophenolate for all patients, associated with ATG in 39 patients (76." | 5.30 | Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. ( Adaeva, R; Banet, A; Bastos, J; Battipaglia, G; Belhocine, R; Brissot, E; de Wyngaert, ZV; Duléry, R; Giannotti, F; Isnard, F; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Mohty, M; Paviglianiti, A; Rubio, MT; Ruggeri, A; Sestili, S; Vekhoff, A, 2019) |
| "Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by posttransplantation high-dose cyclophosphamide (PT-CY): the myeloablative (MA) conditioning consisted of thiotepa, busulfan, fludarabine (n = 35), or total body irradiation (TBI), fludarabine (n = 15)." | 5.17 | Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. ( Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R, 2013) |
| " This study reports the results of UD-CBT in 22 adults with hematologic malignancies following conditioning with thiotepa, busulfan, cyclophosphamide, and antithymocyte globulin in 21, with thiotepa, fludarabine, and antithymocyte globulin in 1, and graft-versus-host disease (GVHD) prophylaxis with cyclosporine and prednisone." | 5.09 | Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. ( Andreu, R; Barragán, E; Benlloch, L; Bolufer, P; Cervera, J; de La Rubia, J; García, I; Jarque, I; Jiménez, C; Larrea, L; Martín, G; Martínez, J; Marty, ML; Mollá, S; Moscardó, F; Planelles, D; Plumé, G; Regadera, AI; Saavedra, S; Sanz, GF; Sanz, MA; Senent, L; Soler, MA; Solves, P, 2001) |
| "We compared outcomes between 5 mg/kg (T5) and 10 mg/kg (T10) thiotepa-based conditioning regimens in 29 adults who underwent allogeneic stem-cell transplantation for hematologic malignancies." | 3.88 | Thiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem-Cell Transplantation. ( Assi, H; Bazarbachi, A; El-Cheikh, J; Haffar, B; Mahfouz, R; Massoud, R; Moukalled, N; Zahreddine, A, 2018) |
| " In order to decrease nonrelapse mortality, and enhance the graft-versus-tumor effect, a program was designed in which a reduced conditioning with thiotepa, fludarabine, and cyclophosphamide was associated with programmed reinfusions of donor lymphocytes for patients without graft-versus-host disease (GVHD), not achieving clinical and molecular remission after transplantation." | 3.71 | Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. ( Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F, 2002) |
| " Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and antithymocyte globulin (ATG)." | 3.70 | Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. ( Bacigalupo, A; Barbanti, M; Berisso, G; Bregante, S; Bruno, B; Casarino, L; Di Grazia, C; Dominietto, A; Ficai, G; Ghinatti, C; Gualandi, F; Lamparelli, T; Raiola, AM; Sacchi, N; Sessarego, M; van Lint, MT; Verdiani, S, 2000) |
| "Forty-seven patients with advanced hematologic malignancies with a median age of 23 years (30 adults and 17 children) were treated." | 2.77 | Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. ( Bassett, R; Champlin, RE; Chan, KW; Ciurea, SO; Couriel, DR; de Lima, M; Fernandez-Vina, M; Hamerschlak, N; Hosing, CM; Jones, RB; Karduss Aurueta, AJ; Kebriaei, P; McMannis, J; Nieto, Y; Petropoulos, D; Qazilbash, M; Rondon, G; Saliba, RM; Sharma, M; Shpall, EJ; Worth, LL, 2012) |
| "Toxicity included mostly infections." | 2.75 | Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. ( Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL, 2010) |
| "All but four had advanced hematologic malignancies." | 2.71 | Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. ( Amin, K; Chen, YH; Cheung, T; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sosman, J; Stock, W; van Besien, K; Vijayakumar, S; Wickrema, A; Yassine, M, 2003) |
| "All patients had high-risk hematologic malignancies, were younger than 20 years, and were in complete cytological remission at the time of allo-HSCT." | 1.91 | Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders. ( Andersson, BS; Anurathapan, U; Hongeng, S; Pakakasama, S; Pongpitcha, P; Sirachainan, N; Songdej, D; Tannumsaeung, S, 2023) |
| "However, the effect of Gilbert's syndrome on the disposition of some drugs can lead to unexpected toxicity." | 1.43 | Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study. ( Evans, AT; Gooley, TA; McCune, JS; McDonald, GB; Ostrow, JD; Schoch, G, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 10 (38.46) | 24.3611 |
| 2020's | 4 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Tannumsaeung, S | 3 |
| Anurathapan, U | 3 |
| Pakakasama, S | 3 |
| Pongpitcha, P | 3 |
| Songdej, D | 3 |
| Sirachainan, N | 3 |
| Andersson, BS | 3 |
| Hongeng, S | 3 |
| Othman, T | 1 |
| Quan, MA | 1 |
| Zhang, S | 1 |
| Gaut, D | 1 |
| Young, PA | 1 |
| Mahmood, O | 1 |
| Abdulhaq, H | 1 |
| Shieh, K | 1 |
| Reid, J | 1 |
| Brem, EA | 1 |
| Hariharan, N | 1 |
| Heyman, B | 1 |
| Tuscano, J | 1 |
| Peric, Z | 1 |
| Mohty, R | 1 |
| Bastos, J | 2 |
| Brissot, E | 2 |
| Battipaglia, G | 2 |
| Belhocine, R | 2 |
| Sestili, S | 2 |
| Giannotti, F | 2 |
| Vekhoff, A | 2 |
| Ledraa, T | 2 |
| Legrand, O | 2 |
| Lapusan, S | 2 |
| Isnard, F | 2 |
| Labopin, M | 1 |
| Bonnin, A | 1 |
| Mediavilla, C | 2 |
| Rubio, MT | 2 |
| Ruggeri, A | 2 |
| Duléry, R | 2 |
| Malard, F | 2 |
| Mohty, M | 2 |
| Esquirol, A | 1 |
| Querol, S | 1 |
| Garcia-Cadenas, I | 1 |
| Novelli, S | 1 |
| Garrido, A | 1 |
| Saavedra, S | 2 |
| Moreno, C | 1 |
| Granell, M | 1 |
| Caballero, A | 1 |
| Brunet, S | 1 |
| Briones, J | 1 |
| Martino, R | 1 |
| Sierra, J | 1 |
| El-Cheikh, J | 1 |
| Massoud, R | 1 |
| Moukalled, N | 1 |
| Haffar, B | 1 |
| Assi, H | 1 |
| Zahreddine, A | 1 |
| Mahfouz, R | 1 |
| Bazarbachi, A | 1 |
| Paviglianiti, A | 1 |
| Banet, A | 1 |
| de Wyngaert, ZV | 1 |
| Adaeva, R | 1 |
| Milone, G | 1 |
| Leotta, S | 1 |
| Cupri, A | 1 |
| Fauci, AL | 1 |
| Spina, P | 1 |
| Parisi, M | 1 |
| Berritta, D | 1 |
| Tripepi, G | 1 |
| Baronciani, D | 1 |
| Depau, C | 1 |
| Targhetta, C | 1 |
| Derudas, D | 1 |
| Culurgioni, F | 1 |
| Tandurella, I | 1 |
| Latte, G | 1 |
| Palmas, A | 1 |
| Angelucci, E | 1 |
| McDonald, GB | 2 |
| Evans, AT | 1 |
| McCune, JS | 1 |
| Schoch, G | 1 |
| Ostrow, JD | 1 |
| Gooley, TA | 1 |
| Ciurea, SO | 2 |
| Saliba, R | 1 |
| Rondon, G | 2 |
| Pesoa, S | 1 |
| Cano, P | 1 |
| Fernandez-Vina, M | 2 |
| Qureshi, S | 1 |
| Worth, LL | 2 |
| McMannis, J | 2 |
| Kebriaei, P | 2 |
| Jones, RB | 2 |
| Korbling, M | 1 |
| Qazilbash, M | 2 |
| Shpall, EJ | 2 |
| Giralt, S | 1 |
| de Lima, M | 2 |
| Champlin, RE | 2 |
| Gajewski, J | 1 |
| Saliba, RM | 1 |
| Hamerschlak, N | 1 |
| Karduss Aurueta, AJ | 1 |
| Bassett, R | 1 |
| Petropoulos, D | 1 |
| Chan, KW | 1 |
| Couriel, DR | 1 |
| Sharma, M | 1 |
| Hosing, CM | 1 |
| Nieto, Y | 1 |
| Sanz, J | 1 |
| Boluda, JC | 1 |
| Martín, C | 1 |
| González, M | 1 |
| Ferrá, C | 1 |
| Serrano, D | 1 |
| de Heredia, CD | 1 |
| Barrenetxea, C | 1 |
| Martinez, AM | 1 |
| Solano, C | 1 |
| Sanz, MA | 2 |
| Sanz, GF | 2 |
| Raiola, AM | 3 |
| Dominietto, A | 3 |
| Ghiso, A | 1 |
| Di Grazia, C | 3 |
| Lamparelli, T | 3 |
| Gualandi, F | 3 |
| Bregante, S | 3 |
| Van Lint, MT | 3 |
| Geroldi, S | 1 |
| Luchetti, S | 1 |
| Ballerini, F | 1 |
| Miglino, M | 1 |
| Varaldo, R | 1 |
| Bacigalupo, A | 4 |
| Larsen, JT | 1 |
| Hogan, WJ | 1 |
| Micallef, IN | 1 |
| Dispenzieri, A | 1 |
| Gertz, MA | 1 |
| Inwards, DJ | 1 |
| Tun, HW | 1 |
| Roy, V | 1 |
| Geyer, SM | 1 |
| Allred, JB | 1 |
| Wu, W | 1 |
| Ansell, SM | 1 |
| Elliott, MA | 1 |
| Tefferi, A | 1 |
| Porrata, LF | 1 |
| Gastineau, DA | 1 |
| Lacy, MQ | 1 |
| Litzow, MR | 1 |
| van Besien, K | 1 |
| Devine, S | 1 |
| Wickrema, A | 1 |
| Jessop, E | 1 |
| Amin, K | 1 |
| Yassine, M | 1 |
| Maynard, V | 1 |
| Stock, W | 1 |
| Peace, D | 1 |
| Ravandi, F | 1 |
| Chen, YH | 1 |
| Cheung, T | 1 |
| Vijayakumar, S | 1 |
| Hoffman, R | 1 |
| Sosman, J | 1 |
| Alessandrino, EP | 2 |
| Bernasconi, P | 2 |
| Colombo, AA | 2 |
| Caldera, D | 2 |
| Malcovati, L | 2 |
| Troletti, D | 1 |
| Vanelli, L | 1 |
| Varettoni, M | 2 |
| Montanari, F | 1 |
| Lazzarino, M | 2 |
| Occhini, D | 1 |
| Ibatici, A | 1 |
| Bruno, B | 2 |
| Frassoni, F | 1 |
| Mahendra, P | 1 |
| Johnson, D | 1 |
| Scott, MA | 1 |
| Jestice, HK | 1 |
| Hood, IM | 1 |
| Ager, S | 1 |
| Bass, G | 1 |
| Barker, P | 1 |
| Boraks, PA | 1 |
| Bloxham, DM | 1 |
| Baglin, TP | 1 |
| Marcus, RE | 1 |
| Galotto, M | 1 |
| Berisso, G | 2 |
| Delfino, L | 1 |
| Podesta, M | 1 |
| Ottaggio, L | 1 |
| Dallorso, S | 1 |
| Dufour, C | 1 |
| Ferrara, GB | 1 |
| Abbondandolo, A | 1 |
| Dini, G | 1 |
| Cancedda, R | 1 |
| Quarto, R | 1 |
| Lee, JL | 1 |
| Gooley, T | 1 |
| Bensinger, W | 1 |
| Schiffman, K | 1 |
| Demirer, T | 1 |
| Ilhan, O | 1 |
| Mandel, NM | 1 |
| Arat, M | 1 |
| Günel, N | 1 |
| Celebi, H | 1 |
| Ustün, C | 1 |
| Akan, H | 1 |
| Demirer, S | 1 |
| Aydintuğ, S | 1 |
| Uysal, A | 1 |
| Koç, H | 1 |
| Barbanti, M | 1 |
| Sacchi, N | 1 |
| Ficai, G | 1 |
| Ghinatti, C | 1 |
| Sessarego, M | 1 |
| Casarino, L | 1 |
| Verdiani, S | 1 |
| Fujimaki, K | 1 |
| Maruta, A | 1 |
| Yoshida, M | 1 |
| Sakai, R | 1 |
| Tanabe, J | 1 |
| Koharazawa, H | 1 |
| Kodama, F | 1 |
| Asahina, S | 1 |
| Minamizawa, M | 1 |
| Matsuzaki, M | 1 |
| Fujisawa, S | 1 |
| Kanamori, H | 1 |
| Ishigatsubo, Y | 1 |
| Planelles, D | 1 |
| Senent, L | 1 |
| Cervera, J | 1 |
| Barragán, E | 1 |
| Jiménez, C | 1 |
| Larrea, L | 1 |
| Martín, G | 1 |
| Martínez, J | 1 |
| Jarque, I | 1 |
| Moscardó, F | 1 |
| Plumé, G | 1 |
| Andreu, R | 1 |
| Regadera, AI | 1 |
| García, I | 1 |
| Mollá, S | 1 |
| Solves, P | 1 |
| de La Rubia, J | 1 |
| Bolufer, P | 1 |
| Benlloch, L | 1 |
| Soler, MA | 1 |
| Marty, ML | 1 |
| Bonfichi, M | 1 |
| Pagnucco, G | 1 |
| Bernasconi, C | 1 |
| Corradini, P | 1 |
| Tarella, C | 1 |
| Olivieri, A | 1 |
| Gianni, AM | 1 |
| Voena, C | 1 |
| Zallio, F | 1 |
| Ladetto, M | 1 |
| Falda, M | 1 |
| Lucesole, M | 1 |
| Dodero, A | 1 |
| Ciceri, F | 1 |
| Benedetti, F | 1 |
| Rambaldi, A | 1 |
| Sajeva, MR | 1 |
| Tresoldi, M | 1 |
| Pileri, A | 1 |
| Bordignon, C | 1 |
| Bregni, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen[NCT01991457] | Phase 2 | 19 participants (Actual) | Interventional | 2013-08-27 | Completed | ||
| Prospective Multicenter Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients With Hematologic Malignancies[NCT02385955] | Phase 2 | 39 participants (Anticipated) | Interventional | 2015-04-30 | Not yet recruiting | ||
| Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease[NCT03240731] | Phase 2 | 18 participants (Anticipated) | Interventional | 2017-08-10 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients without relapse of disease at 2 years (NCT01991457)
Timeframe: 2 years post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment | 63.2 |
1 review available for thiotepa and Hematologic Malignancies
| Article | Year |
|---|---|
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmust | 1996 |
13 trials available for thiotepa and Hematologic Malignancies
| Article | Year |
|---|---|
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Diseas | 2019 |
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Fema | 2016 |
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Ce | 2010 |
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cord Blood | 2012 |
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Tra | 2012 |
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan | 2013 |
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Gra | 2013 |
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Graft Surviv | 2003 |
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Female; Graft | 2004 |
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmust | 1996 |
Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Cyclo | 1999 |
A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dose- | 2000 |
Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Femal | 2001 |
13 other studies available for thiotepa and Hematologic Malignancies
| Article | Year |
|---|---|
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem | 2023 |
Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
Topics: Adult; Central Nervous System; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Human | 2023 |
Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.
Topics: Antilymphocyte Serum; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic | 2020 |
When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (t
Topics: Adult; Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Female; Hematologic Neoplas | 2020 |
Thiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem-Cell Transplantation.
Topics: Adult; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Tran | 2018 |
Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytar | 2014 |
Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.
Topics: Adult; Bilirubin; Busulfan; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Fema | 2016 |
Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up.
Topics: Cyclophosphamide; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; | 2007 |
Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone M | 1999 |
Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin.
Topics: Actuarial Analysis; Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Pr | 2000 |
Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response R | 2001 |
Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined M | 2001 |
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graf | 2002 |